Answers are grounded in this paper and cite their sources.
This multicenter retrospective case series characterizes maribavir (MBV) use for cytomegalovirus (CMV) infection in 62 immunocompromised children treated at 18 United States centers from 2015 through 2024. The most common indications for use were suspected antiviral resistance (45.2%), documented resistance (19.4%), and lack of appropriate alternative agents (11.3%). Among 59 participants with detectable CMV DNAemia when their first course began, 66.1% had complete response, 5.1% had partial response, 27.1% had no response, and one relapsed before treatment cessation. CMV DNAemia ≥50,000 IU/mL was associated with a lower response rate, and MBV resistance was identified in four participants. Across 70 total treatment episodes, 21.4% reported adverse events and discontinuation attributed to MBV occurred in 5.7%. Concomitant use of MBV and other anti-CMV directed medications occurred frequently. Although efficacy results are limited by the observational design, these results highlight real-world pediatric experience and safety.
No takes yet. Share an insight, caveat, or question.
Kraft et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: